Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23988534 | 0.89 | KDM4E (0.35) | CYP1A2ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL19660808 | 0.87 | KDM4E (0.38) | CYP1A2ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL23988563 | 0.87 | KDM4E (0.38) | CYP1A2ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL19198573 | 0.84 | KDM4E (0.36) | ADRB2KDM4EHTR1AALDH1A1 | |
| SCHEMBL23837976 | 0.84 | APP (0.40) | CYP1A2ADRB2KDM4ECYP3A4CYP2C19 | |
| SCHEMBL23988618 | 0.83 | KDM4E (0.33) | CYP1A2ADRB2KDM4ECYP3A4CYP2C19 | |
| SCHEMBL18545280 | 0.82 | APP (0.38) | CYP1A2ADRB2KDM4ECYP3A4CYP2C19 | |
| SCHEMBL23988566 | 0.82 | KDM4E (0.34) | CYP1A2ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL23988525 | 0.81 | KDM4E (0.38) | CYP1A2ADRB2KDM4ECYP3A4CYP2C19 | |
| SCHEMBL23988428 | 0.81 | LPAR5 (0.35) | ADRB2ADRB1KDM4EHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340404-A1 | SILANOL COMPOSITIONS AND METHODS OF USE | 3M INNOVATIVE PROPERTIES COMPANY | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340404-A1 | SILANOL COMPOSITIONS AND METHODS OF USE | EPCAM, ITGA8, CD99 | CYP1A2 1429/4885ADRB2 3522/4885ADRB1 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.